Introduction {#s1}
============

Gastric carcinoma is one of the highest cancer-mortality diseases [@pone.0060320-Wagner1]--[@pone.0060320-Catalano1] with a high incidence rate in Asia [@pone.0060320-Ajani1]. A lot of patients are diagnosed at advanced even end stage carcinoma, indicating poor outcomes [@pone.0060320-Tsai1]. For resectable diseases, surgery is considered as the mainstream treatment [@pone.0060320-VanCutsem1]--[@pone.0060320-Chen1]. Adjuvant or neo-adjuvant chemotherapy has also been proven to benefit the survival rate in some studies and meta-analyses [@pone.0060320-Hu2]--[@pone.0060320-Chen2]. For surgically unfit but medically fit patients, palliative chemotherapy is the main treatment [@pone.0060320-VanCutsem1], [@pone.0060320-Roth1], [@pone.0060320-Shah1]--[@pone.0060320-Takayama1]. The regimens of cisplatin and 5-fluorouracil (CF) or epirubicin, cisplatin and 5-fluorouracil (ECF) have been used widely [@pone.0060320-Ohtsu1], and were often considered as the reference regimens for advanced gastric cancer [@pone.0060320-VanCutsem2]. Among new generation chemotherapy regimens, docetaxel, which is a semisynthetic taxane, promoting the assembly and stabilization of microtubules to inhibit the depolymerization [@pone.0060320-Cortes1], has been used more and more extensively with more potent effects [@pone.0060320-Takayama1], [@pone.0060320-Bang1]--[@pone.0060320-Chen3]. The chemotherapy based on docetaxel may be effective [@pone.0060320-Roth2], because docetaxel lacks cross-resistance with other anti-tumor drugs [@pone.0060320-Haller1]. The chemotherapy regimen of docetaxel, cisplatin and 5-fluorouracil (DCF) has been used to treat the advanced stage or metastatic gastric carcinoma with encouraging survival outcomes [@pone.0060320-Yamamoto1]--[@pone.0060320-Ajani3] and better quality of life [@pone.0060320-Ajani4], [@pone.0060320-Sadighi1] in several studies. However, it was reported in some researches [@pone.0060320-Li1]--[@pone.0060320-Roth3] that more toxicity, such as hematotoxicity, happened in DCF than in other regimens. Therefore, evaluation of benefits against the chemotherapy-related toxicities was needed. Present systematic review and meta-analysis were done to evaluate the survival outcomes and toxicities of DCF for palliatively resected, unresectable, recurrent or metastatic gastric carcinoma, compared with those of non-taxane-containing regimens.

Methods {#s2}
=======

No protocol was registered.

Search Strategy {#s2a}
---------------

We searched the electronic databases of PubMed (<http://www.ncbi.nlm.nih.gov/sites/entrez/>), EmBase (<http://www.embase.com/home>), Cochrane Central Register of Controlled Trials (<http://ovidsp.tx.ovid.com/sp-3.4.1b/ovidweb.cgi>), and China National Knowledge Infrastructure Database (<http://acad.cnki.net/Kns55/brief/result.aspx?dbPrefix=CJFQ>) up to July 31, 2011. The search strategy in PubMed was as follows, ("docetaxel"\[Supplementary Concept\] OR docetaxel\[Text Word\]) AND ("stomach neoplasms"\[MeSH Terms\] OR ("stomach"\[All Fields\] AND "neoplasms"\[All Fields\]) OR "stomach neoplasms"\[All Fields\] OR ("gastric"\[All Fields\] AND "cancer"\[All Fields\]) OR "gastric cancer"\[All Fields\]) AND ("humans"\[MeSH Terms\] AND (Clinical Trial\[ptyp\] OR Meta-Analysis\[ptyp\] OR Randomized Controlled Trial\[ptyp\] OR Review\[ptyp\]) AND English\[lang\]). The search strategy was also referred in other electronic databases.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

Only randomized controlled trials (RCTs) were eligible for inclusion. Included patients were diagnosed with palliatively resected, unresectable, recurrent or metastatic gastric carcinoma. Both, patients with previous surgery and without, were acceptable. DCF palliative chemotherapy could be administrated as the first-line regimen. If the control arm was blank or contaminated with taxane, the trials were excluded. Response, survival outcomes or toxicities were mandatory to be reported.

Selection, Assessment and Data Extraction {#s2c}
-----------------------------------------

Two independent reviewers (Chen XL, Yang C) read the title and abstract of every searched citation to select eligible studies for further assessment. Full text of potentially eligible citation was retrieved and determined for inclusion. Jadad scale described by Jadad, et al was used to assess the quality of RCTs [@pone.0060320-Jadad1]. Data was extracted independently by two reviewers mentioned above. Primary outcome measures included 1) 1-year and 2-year overall survival (OS) rates. Secondary outcome measures were 2) median survival time (MST), 3) time to progression (TTP), 4) response rate (WHO Criteria) [@pone.0060320-Miller1] containing complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) and overall response rate (ORR), 5) toxicities (grade I--IV) and 6) chemotherapy-related death. ORR meant the combination of CR and PR. Study sample and regimen details were also extracted. Any disagreements in studies assessment and data collection were discussed and resolved by a third party (Hu JK, Chen XZ) as the referees.

Statistical Analysis {#s2d}
--------------------

The statistical analysis was performed by Reviewer Manager (RevMan) software, version 5.0 offered by The Cochrane Collaboration. The Mantel-Haenszel (M-H) test was used for comparison of dichotomous data and risk ratio (RR) or risk difference (RD) estimate. The 95% confidence interval (CI) of RR or RD was also calculated. A two-sided P value less than 0.05 was considered as a significant difference. Between-trials heterogeneity was evaluated by the Chi-square test; P value less than 0.1 was considered as significant heterogeneity [@pone.0060320-Higgins1]. Providing heterogeneity existed, random effect model was used for meta-analysis; otherwise fixed effect model was used.

Results {#s3}
=======

Literatures Search and Selection {#s3a}
--------------------------------

The literature search and selection procedure were shown in [Figure 1](#pone-0060320-g001){ref-type="fig"}. Totally, 12 RCTs were eligible for analysis and 1089 patients with palliatively resected, unresectable, recurrence or metastatic gastric cancer were involved (549 in DCF vs 540 in control) [@pone.0060320-Sadighi1], [@pone.0060320-Roth3], [@pone.0060320-Chu1]--[@pone.0060320-Gao1] (Table1). The sample size of individual RCT ranged from 36 to 445. There were no significant differences in the baselines between DCF and controlled group in these studies, as reported. In these studies, DCF were compared with cisplatin and fluorouracil (CF), epirubicin, cisplatin and fluorouracil (ECF), oxaliplatin and fluorouracil (FOLFOX4), etoposide and fluorouracil (EF) regimens.

![Literature search and selection procedure.](pone.0060320.g001){#pone-0060320-g001}

10.1371/journal.pone.0060320.t001

###### Summary information of included RCTs.

![](pone.0060320.t001){#pone-0060320-t001-1}

  Studies                                                                                                                                                 Demographic data                                                                                                                                                      Intervention& control                                                                                           Outcome measures           Jadad scores
  ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- --------------
  **Chu JH, et al** [@pone.0060320-Chu1]20061 center in China                                                       40 patients with recurrence or metastaticgastric carcinoma chemotherapy-naïvewithin 1 month.                                                     **DCF:** docetaxel 25 mg/m^2^, cisplatin 35 mg/m^2^, 5-FU750 mg/m^2^.3--4 cycles.**CF:** cisplatin 20 mg/m^2^, 5-FU 1000 mg/m2. 3--4 cycles.                          ORR, MST, TTP andtoxicities          1
  **Van Cutsem E, et al** [@pone.0060320-VanCutsem4] 200672 centers in 16 countries.                     457 patients with metastaticor locally advanced/recurrentgastric cancer.12 patients without treatmentwere excluded.                         **DCF**: docetaxel 75 mg/m^2^, cisplatin 75 mg/m^2^ and 5-FU750 mg/m^2^. Median6 (1--16) cycles. **CF**: cisplatin100 mg/m^2^ and 5-FU1000 mg/m^2^. Median 4 (1--12) cycles.        ORR,TTP, OS, toxicities and QOL        2
  **Sadighi S, et al** [@pone.0060320-Sadighi1]20061 center in Iran                     86 patients with primary or recurrent gastric cancer(III--IV stage). 15 patients did not completethe questionnaires andwere excluded in QOL analyses.         **DCF**: docetaxel 60 mg/m^2^, cisplatin 60 mg/m^2^ and 5-FU750 mg/m^2^. 3--6 cycles**ECF**: epirubicin 60 mg/m^2^, cisplatin 60 mg/m^2^ and 5-FU750 mg/m^2^. 3--6cycles.                    ORR and QOL                  2
  **Li XQ, et al** [@pone.0060320-Li2]20071 center in China                                                                                 60 patients with stage IV gastric carcinoma.                                                                             **DCF**: docetaxel 25 mg/m^2^, cisplatin 6 mg/m^2^ and 5-FU200 mg/m^2^. 2 cycles.**CF**: cisplatin 6 mg/m^2^ and 5-FU 200 mg/m^2^. 2 cycles.                            ORR, MST andtoxicities             1
  **Roth AD, et al** [@pone.0060320-Roth3]200713 centers in 4countries                                121 patients with unresectablegastric cancer,metastatic or locally carcinoma. 2 patients withouttreatment were excluded.                    **DCF**: docetaxel 85 mg/m^2^, cisplatin 75 mg/m^2^, and5-FU300 mg/m^2^. Median 4 cycles.**ECF**: epirubicin 50 mg/m^2^, cisplatin 60 mg/m^2^, 5-FU 200 mg/m^2^.Median 5.5 cycles.       ORR, OS, toxicitiesand QOL           2
  **Wu GC, et al** [@pone.0060320-Wu1]20081 center in China                                                             58 patients with stage III--IV gastriccarcinoma received first orsecondary treatment.                                                           **DCF:** docetaxel 75 mg/m^2^, cisplatin 75 mg/m^2^, 5-FU 750 mg/m^2^.2 cycles.**CF:** cisplatin 75 m/m^2^, 5-FU 750 mg/m^2^. 2 cycles                               ORR, MST, andtoxicities            1
  **Zhang FL, et al** [@pone.0060320-Zhang1]20081 center in China                                                           50 chemotherapy-naive patients with localrecurrence or metastatic carcinoma.                                                      **DCF:** docetaxel 75 mg/m^2^, cisplatin 25 mg/m^2^, 5-FU 500 mg/m^2^. More than2 cycles.**CF:** cisplatin 25 m/m^2^, 5-FU 500 mg/m^2^.More than 2 cycles.                       ORR and Toxicities               2
  **Hou AJ, et al** [@pone.0060320-Hou1]20091 center in China                                                40 patients with stage IIIB--IV after gastrectomy orpalliative surgery. 4 patients could not be evaluated.                                  **DCF:** docetaxel 40 mg/m^2^, cisplatin 30 mg/m^2^ and 5-FU 200 mg/m^2^.More than 2 cycles.**ELF:** etoposide 120 mg/m^2^, 5-FU 500 mg/m^2^. More than ^2^ cycles.                   ORR, OS, MST andQOL              3
  **Zhao F, et al** [@pone.0060320-Zhao1]20091 center in China                               31 gastric cancer patients in DCF arm and32 in FOLFOX4 arm with recurrenceafter radical gastrectomy or withoutsurgery because ofmetastasis.               **DCF:** docetaxel 75 mg/m^2^, cisplatin 20 mg/m^2^ and 5-FU 350 mg/m^2^. Median 3.1 cycles.**FOLFOX4:** oxaliplatin 100 mg/m^2^ and5-FU 400 mg/m^2^.Median 3.2 cycles.                  ORR, TTP and MST                1
  **Shen YC, et al** [@pone.0060320-Shen1]20091 center in China.                                                   48 chemotherapy-naive patients with late stage gastric carcinoma after noor palliative surgery.                                                **DCF:** docetaxel 35 mg/m^2^, cisplatin 6 mg/m^2^ and 5-FU250 mg/m^2^. 3--4 cycles**CF:** cisplatin 75 mg/m^2^ and 5-FU 1000 mg/m^2^. 3--4 cycles                         ORR, TTP andtoxicities             1
  **Liang B, et al** [@pone.0060320-Liang1]20101 center in China                                              58 patients in DCF arm and control armwith advanced gastric cancer expectedto survive more than3 months.                          **DCF:** docetaxel 75 mg/m^2^, cisplatin 75 mg/m^2^ and 5-FU 300 mg/m^2^.More than 2 cycles.**ECF:** epirubicin 50 mg/m^2^, cisplatin 60 mg/m^2^, 5-FU 200 mg/m^2^. Morethan 2 cycles.         ORR and toxicities               1
  **Gao H, et al** [@pone.0060320-Gao1]20101 center in China                                                                             64 patients with stage IIIB--IV gastric carcinoma.                                                     **DCF:** docetaxel 60 mg/m^2^, cisplatin 25 mg/m^2^, 5-FU 1000 mg/m^2^. More than 2 cycles.**ECF:** epirubicin 50 mg/m^2^, cisplatin 25 mg/m^2^, 5-FU 1000 mg/m^2^. Morethan 2 cycles.           ORR, OS and QOL                3

**Abbreviations: DCF:** docetaxel, cisplatin and fluorouracil; **CF:** cisplatin and fluorouracil; **ECF:** epirubicin, cisplatin and fluorouracil; **FOLFOX4:** oxaliplatin and fluorouracil; **EF:** etoposide and fluorouracil; **FU:** fluorouracil; **ORR:** overall response rate; **TTP:** time to progression; **QOL:** quality of life; **MST**: median survival time; **OS:** overall survival.

Response {#s3b}
--------

Response rate was based on WHO Criteria [@pone.0060320-Miller1]. The overall response rate (ORR) combined of CR and PR, was 44.4% (244/549) vs 30.6% (165/540) in DCF and non-taxane-containing regimens, respectively. Its meta-analysis showed significantly better ORR of DCF regimen (RR = 1.45, 95% CI 1.24--1.69, p\<0.00001) ([Figure 2](#pone-0060320-g002){ref-type="fig"}). The subgroup meta-analysis results of CR, PR, SD and PD were listed in [Table 2](#pone-0060320-t002){ref-type="table"}. CR and SD rates were not significantly different between two groups ([Table 2](#pone-0060320-t002){ref-type="table"}). DCF regimen was able to noticeably increase PR rate (38.8% vs 27.9%, RR = 1.39, 95%CI 1.16--1.65, p = 0.0003), as well as reduce PD rate (18.9% vs 33.3%, RR = 0.65, 95%CI 0.51--0.83, p = 0.0005) (Forest plots not shown).

![Forest plot of overall response rate.](pone.0060320.g002){#pone-0060320-g002}

10.1371/journal.pone.0060320.t002

###### Response comparison between DCF and non-taxane-containing chemotherapy.

![](pone.0060320.t002){#pone-0060320-t002-2}

  Response                   Study   DCF   Non-taxane-containing   PooledRR   95% CI   P value   Model   References                                
  ------------------------- ------- ----- ----------------------- ---------- -------- --------- ------- ------------ ------------ -------- ------- -------------------------------------------------------------------
  CompleteResponse (CR)       11     25             505              5.0%       14       498     2.8%       1.69      0.91--3.14    0.10    Fixed   [@pone.0060320-Roth3], [@pone.0060320-Chu1]--[@pone.0060320-Gao1]
  PartialResponse (PR)        11     196            505             38.8%      139       498     27.9%      1.39      1.16--1.65   0.0003   Fixed   [@pone.0060320-Roth3], [@pone.0060320-Chu1]--[@pone.0060320-Gao1]
  StableDisease (SD)           9     122            444             27.5%      136       438     31.1%      0.88      0.72--1.08    0.23    Fixed           [@pone.0060320-VanCutsem4]--[@pone.0060320-Gao1]
  ProgressiveDisease (PD)      9     84             444             18.9%      146       438     33.3%      0.65      0.51--0.83   0.0005   Fixed           [@pone.0060320-VanCutsem4]--[@pone.0060320-Gao1]

**Abbreviations: DCF:** docetaxel, cisplatin and fluorouracil; **RR:** risk ratio.

Survival Outcomes {#s3c}
-----------------

Only 3 RCTs reported the 1-year OS rate and its details ranging from 40.0% to 41.9% in DCF and 30.0% to 40.0% in non-taxane-containing regimens [@pone.0060320-Chu1], [@pone.0060320-VanCutsem4], [@pone.0060320-Zhao1]. The cumulative 1-year OS rate was 40.1% (109/272) in DCF and 33.0% (91/276) in non-taxane-containing regimens. Meta-analysis demonstrated no significant difference in 1-year OS rate (RR = 1.22, 95% CI 0.97--1.52, p = 0.08). However only one RCT analyzed 2-year OS rate showing significantly better 2-year OS rate in DCF regimen (18.0% vs 9.0%, RR = 2.03, p = 0.006) [@pone.0060320-Roth3] ([Figure 3](#pone-0060320-g003){ref-type="fig"}).

![Forest plot of subgroup analysis of 1-year and 2-year overall survival rates.](pone.0060320.g003){#pone-0060320-g003}

MST was reported in 9 RCTs and it ranged from 9.0 to 14.6 months in DCF and 5.0 to 12.0 months in non-taxane-containing regimens ([Table 3](#pone-0060320-t003){ref-type="table"}). Six RCTs analyzed median TTP which ranged from 4.6 to 6.8 months in DCF and 2.6 to 5.5 months in non-taxane-containing regimens ([Table 3](#pone-0060320-t003){ref-type="table"}). Comparison of MST and median TTP between two groups by one-way ANOVA test (SPSS 13.0) demonstrated significantly prolonged MST in DCF regimen (p = 0.039) ([Figure 4](#pone-0060320-g004){ref-type="fig"}). Median TTP showed a trend of prolongation in DCF regimen without reaching statistically significant difference (p = 0.054) ([Figure 5](#pone-0060320-g005){ref-type="fig"}).

![Median survival time (MST) comparison.](pone.0060320.g004){#pone-0060320-g004}

![Median time-to-progression (TTP) comparison.](pone.0060320.g005){#pone-0060320-g005}

10.1371/journal.pone.0060320.t003

###### Details information of MST and TTP reported by some RCTs.

![](pone.0060320.t003){#pone-0060320-t003-3}

  Studies                                          MST (range)            P value        Median TTP (range)        P value                           
  ------------------------------------------- --------------------- ------------------- -------------------- ------------------- ------------------- ---------
  Chu JH, et al [@pone.0060320-Chu1]                  10.0                  7.8                  --                  5.0                 3.5            --
  Van CE, et al [@pone.0060320-VanCutsem4]       9.2 (8.4--10.6)      8.6 (7.2--9.5)            0.02           5.6 (4.9--5.9)      3.7 (3.4--4.5)     \<0.001
  Sadighi S, et al [@pone.0060320-Sadighi1]       12.0 (7--17)         12.0 (8--14)              --                  --                  --             --
  Li XQ, et al [@pone.0060320-Li2]                     9.0                  5.0                \<0.05                4.8                 2.6          \<0.05
  Roth AD, et al [@pone.0060320-Roth3]          10.4 (8.3--12.0)      8.3 (7.2--13.0)            --            4.6 (3.5--5.6)      4.9 (3.2--6.1)       --
  Wu GC, et al [@pone.0060320-Wu1]                    14.6                  9.8                \<0.05                --                  --             --
  Hou AJ, et al [@pone.0060320-Hou1]               9.0 (2--18)          8.0 (2--18)            \>0.05                --                  --             --
  Zhao F, et al [@pone.0060320-Zhao1]                  9.0                  8.8                \>0.05                5.5                 5.3          \>0.05
  Gao H, et al [@pone.0060320-Gao1]            10.81 (8.42--13.20)   8.06 (6.46--9.67)         0.038          6.81 (5.52--8.11)   5.13 (4.18--6.07)    0.041

**Abbreviation: MST:** median survival time; **TTP:** time to progression; **DCF:** docetaxel, cisplatin and fluorouracil.

Toxicities {#s3d}
----------

In these studies, the toxicities were graded from I to IV according to WHO Criteria, National Cancer Institute-Common Terminology Criteria and National Cancer Institute of Canada Common Toxicity Criteria. These three different criteria are comparable. We compared grade I--IV and grade III--IV in both arms according to reports information ([Table 4](#pone-0060320-t004){ref-type="table"}). The major grade I--IV toxicities (accumulated rate \>5%) of DCF regimen were hematological toxicity including leucopenia (81.7%), neutropenia (84.1%), febrile neutropenia (27.3%), thrombocytopenia (24.7%), anemia (81.6%), and digestive systemic toxicity including diarrhea (58.9%), nausea/vomiting (59.2%), stomatitis (56.2%), anorexia (45.8%), constipation (26.3%), liver damage (7.3%). Other toxicities were neurological damage (33.7%), alopecia (73.5%), anaphylaxis (11.8%), infection (16.2%), fatigue (54.6%) and fluid retention (6.7%).

10.1371/journal.pone.0060320.t004

###### Toxicities comparison between DCF and non-taxane-containing chemotherapy.

![](pone.0060320.t004){#pone-0060320-t004-4}

  Toxicities                     Study   DCF   Non-taxane-containing   Pooled   95% CI   P value   Model   References                                      
  ----------------------------- ------- ----- ----------------------- -------- -------- --------- ------- ------------ -------------- ----------- -------- -------------------------------------------------------------------------------------------------------------------------------------------
  Leucopenia (I--IV)               6     282            345            81.7%     228       346     65.9%   RR = 1.25     1.15--1.35    \<0.00001   Fixed                  [@pone.0060320-Chu1]--[@pone.0060320-Li2], [@pone.0060320-Hou1], [@pone.0060320-Shen1], [@pone.0060320-Gao1]
  III--IV                          5     185            342            54.1%      97       342     28.4%   RR = 1.72     1.15--2.56      0.008     Random              [@pone.0060320-Roth3], [@pone.0060320-VanCutsem4], [@pone.0060320-Li2], [@pone.0060320-Hou1], [@pone.0060320-Gao1]
  Neutropenia (I--IV)              4     254            302            84.1%     215       303     71.0%   RR = 1.19     1.11--1.28    \<0.00001   Fixed                          [@pone.0060320-VanCutsem4], [@pone.0060320-Hou1], [@pone.0060320-Zhao1], [@pone.0060320-Gao1]
  III--IV                          4     185            302            61.3%     128       303     42.2%   RR = 1.46     1.28--1.66    \<0.00001   Fixed                          [@pone.0060320-VanCutsem4], [@pone.0060320-Hou1], [@pone.0060320-Zhao1], [@pone.0060320-Gao1]
  Febrile neutropenia (I--IV)      2     69             253            27.3%      30       256     11.7%   RR = 2.33     1.57--3.44    \<0.0001    Fixed                                                [@pone.0060320-VanCutsem4], [@pone.0060320-Gao1]
  III--IV                          2     17             73             23.3%      7        72      9.7%    RR = 2.37     1.10--5.09      0.03      Fixed                                                   [@pone.0060320-Roth3], [@pone.0060320-Gao1]
  Thrombocytopenia (I--IV)         5     82             332            24.7%     102       334     30.5%   RR = 1.22     0.64--2.32      0.55      random              [@pone.0060320-VanCutsem4], [@pone.0060320-Li2], [@pone.0060320-Hou1], [@pone.0060320-Zhao1], [@pone.0060320-Gao1]
  III--IV                          6     19             373             5.1%      48       357     13.4%   RR = 0.60     0.33--1.08      0.09      Fixed    [@pone.0060320-Roth3], [@pone.0060320-VanCutsem4], [@pone.0060320-Li2], [@pone.0060320-Hou1], [@pone.0060320-Zhao1], [@pone.0060320-Gao1]
  Anemia (I--IV)                   5     271            332            81.6%     265       334     79.3%   RR = 1.03     0.97--1.10      0.28      Fixed               [@pone.0060320-VanCutsem4], [@pone.0060320-Li2], [@pone.0060320-Hou1], [@pone.0060320-Zhao1], [@pone.0060320-Gao1]
  III--IV                          5     47             332            14.2%      61       334     18.3%   RR = 0.73     0.48--1.12      0.15      Fixed               [@pone.0060320-VanCutsem4], [@pone.0060320-Li2], [@pone.0060320-Hou1], [@pone.0060320-Zhao1], [@pone.0060320-Gao1]
  Diarrhea (I--IV)                 5     192            326            58.9%     122       330     37.0%   RR = 1.59     1.36--1.87    \<0.00001   Fixed                             [@pone.0060320-Chu1]--[@pone.0060320-Li2], [@pone.0060320-Zhao1], [@pone.0060320-Shen1]
  III--IV                          4     49             323            15.2%      20       326     6.1%    RR = 2.82     1.62--4.89     0.0002     Fixed                          [@pone.0060320-Roth3], [@pone.0060320-VanCutsem4], [@pone.0060320-Li2], [@pone.0060320-Zhao1]
  Nausea/vomiting (I--IV)          7     223            377            59.2%     235       379     62.0%   RR = 0.96     0.86--1.07      0.42      Fixed                  [@pone.0060320-Chu1]--[@pone.0060320-Li2], [@pone.0060320-Hou1]--[@pone.0060320-Shen1], [@pone.0060320-Gao1]
  III--IV                          6     49             374            13.1%      51       375     13.6%   RR = 0.97     0.68--1.38      0.85      Fixed    [@pone.0060320-Roth3], [@pone.0060320-VanCutsem4], [@pone.0060320-Li2], [@pone.0060320-Hou1], [@pone.0060320-Zhao1], [@pone.0060320-Gao1]
  Stomatitis (I--IV)               2     141            251            56.2%     142       254     55.9%   RR = 1.01     0.86--1.17      0.94      Fixed                                                 [@pone.0060320-VanCutsem4], [@pone.0060320-Li2]
  III--IV                          3     49             292            16.8%      63       294     21.4%   RR = 0.79     0.57--1.09      0.15      Fixed                                     [@pone.0060320-Roth3], [@pone.0060320-VanCutsem4], [@pone.0060320-Li2]
  Anorexia (I--IV)                 2     116            253            45.8%     116       256     45.3%   RR = 1.01     0.84--1.22      0.90      Fixed                                                [@pone.0060320-VanCutsem4], [@pone.0060320-Gao1]
  III--IV                          2     28             253            11.1%      23       256     9.0%    RR = 1.23     0.73--2.08      0.44      Fixed                                                [@pone.0060320-VanCutsem4], [@pone.0060320-Gao1]
  Constipation (I--IV)             1      5             19             26.3%      2        17      11.8%   RR = 2.24    0.50--10.06      0.29      Fixed                                                              [@pone.0060320-Hou1]
  III--IV                          1      0             19              0.0%      0        17      0.0%    RD = 0.15    −0.10--0.40      0.25      Fixed                                                              [@pone.0060320-Hou1]
  Liver damage (I--IV)             3      6             82              7.3%      7        81      8.6%    RR = 0.84     0.29--2.42      0.75      Fixed                                        [@pone.0060320-Hou1], [@pone.0060320-Zhao1], [@pone.0060320-Gao1]
  III--IV                          3      0             82              0.0%      0        81      0.0%    RD = 0.00    −0.04--0.04      1.00      Fixed                                        [@pone.0060320-Hou1], [@pone.0060320-Zhao1], [@pone.0060320-Gao1]
  Neurological                     2     85             252            33.7%      66       256     25.8%   RR = 0.41     0.02--9.09      0.58      Random                                               [@pone.0060320-VanCutsem4], [@pone.0060320-Zhao1]
  damage(I--IV)                                                                                                                                            
  III--IV                          3     19             293             6.5%      8        296     2.7%    RR = 2.39     1.07--5.36      0.03      Fixed                                    [@pone.0060320-Roth3], [@pone.0060320-VanCutsem4], [@pone.0060320-Zhao1]
  Alopecia (I--IV)                 2     36             49             73.5%      7        47      14.9%   RR = 3.75    1.01--13.84      0.05      Random                                                   [@pone.0060320-Li2], [@pone.0060320-Hou1]
  III--IV                          3     41             90             45.6%      8        87      9.2%    RR = 8.48    0.16--461.63     0.29      Random                                       [@pone.0060320-Roth3], [@pone.0060320-Li2], [@pone.0060320-Hou1]
  Anaphylaxis (I--IV)              2      6             51             11.8%      1        49      2.0%    RR = 4.11    0.74--22.88      0.11      Fixed                                                   [@pone.0060320-Hou1], [@pone.0060320-Gao1]
  III--IV                          2      0             51              0.0%      0        49      0.0%    RD = 0.00    −0.05--0.05      1.00      Fixed                                                   [@pone.0060320-Hou1], [@pone.0060320-Gao1]
  Infection (I--IV)                2     39             241            16.2%      28       244     11.5%   RR = 1.41     0.90--2.22      0.13      Fixed                                                [@pone.0060320-Chu1], [@pone.0060320-VanCutsem4]
  III--IV                          1     28             221            12.7%      16       224     7.1%    RR = 1.77     0.99--3.19      0.06      Fixed                                                           [@pone.0060320-VanCutsem4]
  Fatigue (I--IV)                  2     131            240            54.6%     108       241     44.8%   RR = 1.22     1.02--1.46      0.03      Fixed                                                [@pone.0060320-VanCutsem4], [@pone.0060320-Hou1]
  III--IV                          2     41             240            17.1%      31       241     12.9%   RR = 1.34     0.87--2.06      0.18      Fixed                                                [@pone.0060320-VanCutsem4], [@pone.0060320-Hou1]
  Fluid retention (I--IV)          1      2             30              6.7%      0        30      0.0%    RR = 5.00    0.25--99.95      0.29      Fixed                                                               [@pone.0060320-Li2]
  III--IV                          1      0             30              0.0%      0        30      0.0%    RD = 0.00    −0.06--0.06      1.00      Fixed                                                               [@pone.0060320-Li2]

**Abbreviations: DCF:** docetaxel, cisplatin and fluorouracil; **RR:** risk ratio; **RD:** risk difference.

The meta-analysis results of these toxicities were listed in [Table 3](#pone-0060320-t003){ref-type="table"} (Forest plots not shown). There was significant increase of toxicities in DCF regimen in leucopenia (I--IV RR = 1.25, p\<0.00001; III--IV RR = 1.72, p = 0.008), neutropenia (I--IV RR = 1.19, p\<0.00001; III--IV RR = 1.46, p\<0.00001), febrile neutropenia (I--IV RR = 2.33, p\<0.0001; III--IV RR = 2.37, p = 0.03), diarrhea (I--IV RR = 1.59, p\<0.00001; III--IV RR = 2.82, p = 0.0002), neurological damage (III--IV RR = 2.39, p = 0.03) and fatigue (I--IV RR = 1.22, p = 0.03). In grade I--IV toxicities, DCF regimen showed major raise of febrile neutropenia and minor raise of leucopenia, neutropenia, and diarrhea. Other toxicities such as thrombocytopenia, anemia, nausea/vomiting, stomatitis, anorexia, constipation, alopecia, neurological damage and infection appeared with no significant differences in both arms. Some toxicities including febrile neutropenia, liver damage, anaphylaxis and fluid retention were rare.

One RCT reported chemotherapy-related deaths within 30 days of the last infusion which were mainly caused by infection in both groups [@pone.0060320-VanCutsem4]. Four RCTs reported no chemotherapy-related mortality during the treatment [@pone.0060320-Roth3], [@pone.0060320-Wu1], [@pone.0060320-Zhang1], [@pone.0060320-Liang1]. The accumulated chemotherapy-related mortality rates were 6.6% (23/349) in DCF and 5.5% (19/343) in non-taxane-containing regimens without significant difference (RR = 1.23, 95%CI 0.69--2.91, p = 0.49) (Forest plot not shown).

Discussion {#s4}
==========

Although our meta-analysis did not show the significant difference of 1-year OS rate between DCF chemotherapy and non-taxane-containing regimens, we found that DCF arm was relatively better than control arms in cumulative 1-year OS rate, MST, median TTP and ORR. Only one study, which had a large sample size (445 patients), reported their 2-year OS rate (DCF 18% vs CF 9%) [@pone.0060320-VanCutsem4]. Many studies preferred to show the MST or OS time, TTP and especially ORR which represented the short survival outcomes. There was an interesting phenomenon in one study, in which DCF arm had shorter median TTP but longer MST than ECF arm [@pone.0060320-Roth3]. According to our results, the difference of ORR was significant between two arms, with DCF having more benefits than control group in short time.

On the toxicity analysis, we found that DCF showed worse hematological toxicity, diarrhea, and fatigue. Many studies reported that these toxicities in both group could be accepted or controlled by granulocyte colony stimulating factors (G-CSF), antiemetic, vitamin B6 and drug discontinuance[@pone.0060320-Roth3], [@pone.0060320-Zhang1], [@pone.0060320-Shen1], [@pone.0060320-Gao1]--[@pone.0060320-Makatsoris1]. Further, the total mortality of treatment, mainly caused by infection, was 6.6% in DCF arm and 5.5% in control arms, and showed no significant difference. Prophylactic antibiotics might be necessary for patients with severe leucopenia. Quality of life (QOL) after chemotherapy was of less focus than survival outcomes. Four RCTs demonstrated that DCF group did not have lower QOL. In fact, it even had obvious improvements in global QOL and Karnofsky performance status as well as prolonged the time to worsening of global health [@pone.0060320-Sadighi1], [@pone.0060320-Roth3], [@pone.0060320-VanCutsem4], [@pone.0060320-Hou1]. Although causing more toxicities, DCF was a relatively safe and acceptable chemotherapy.

In every chemotherapy cycle for three or four weeks, the total dosage of docetaxel was from 105 mg/m^2^ to 300 mg/m^2^, cisplatin from 90 mg/m^2^ to 360 mg/m^2^, and 5-FU from 3000 mg/m^2^ to 15000 mg/m^2^ in these studies. The single dosage of docetaxel was noticeably lower in four studies from China (25 mg/m^2^ to 40 mg/m^2^) [@pone.0060320-Chu1], [@pone.0060320-Li2], [@pone.0060320-Hou1], [@pone.0060320-Shen1], that was about one half of the dosage of three foreign studies (60 mg/m^2^ to 85 mg/m^2^) and five other Chinese studies (60 mg/m^2^ to 75 mg/m^2^) [@pone.0060320-Sadighi1], [@pone.0060320-Roth3], [@pone.0060320-VanCutsem4], [@pone.0060320-Wu1], [@pone.0060320-Zhang1], [@pone.0060320-Zhao1], [@pone.0060320-Liang1], [@pone.0060320-Gao1] in which single dosage was similar to that recommended in National Comprehensive Cancer Network (NCCN) clinical practice guideline in oncology [@pone.0060320-Ajani5]. Similar phenomenon happened in cisplatin. Studies in China showed a noticeably lower single dosage of cisplatin (6 mg/m^2^ to 35 mg/m^2^) [@pone.0060320-Sadighi1], [@pone.0060320-Li2], [@pone.0060320-Zhang1]--[@pone.0060320-Shen1], [@pone.0060320-Gao1] than foreign RCTs [@pone.0060320-Sadighi1], [@pone.0060320-Roth3], [@pone.0060320-VanCutsem4] (60 mg/m^2^ to 75 mg/m^2^) [@pone.0060320-Wu1], [@pone.0060320-Liang1] and NCCN recommendation [@pone.0060320-Ajani5]. From all these, we could see that there was a big difference in approach to dosage of DCF. The reason for this, we believe, was the individual distinctions of people in China and Western countries. Moreover, among Chinese RCTs, there was also a difference in the dosage of docetaxel and cisplatin. The question about which plan has better balance of survival outcomes and toxicities, a bigger single dosage with lower frequencies or a smaller single dosage with higher frequencies, needs further research.

A previous systematic review showed that there was significant difference in ORR but no significant difference in overall survival, when docetaxel was compared with non-taxane-containing regimens, which is in accord to our study [@pone.0060320-Wagner2]. However, in former review non-docetaxel-containing regimens might include both single and combined chemotherapy regiments. If docetaxel alone is compared with combined regimens, it might show relatively inferior efficacy of docetaxel. However, in our review, DCF was compared with other combined chemotherapy in all RCTs, which in our opinion seemed more reasonable.

In retrieved literatures of RCTs on DCF, we found that there were no studies from Japan. On one hand, it can be explained by the fact that we only retrieved the English or Chinese language articles. On the other hand, many studies [@pone.0060320-Yoshida1]--[@pone.0060320-Sato2] in Japan talked about the new generation chemotherapy drug S-1 alone or S-1 combined with other drugs, such as docetaxel, and reported promising effects in treating gastric carcinoma. However, they did not compare S-1 with DCF.

Further, we could see that DCF as palliative chemotherapy was reported in all RCTs. At present, adjuvant single or combined chemotherapy following radical surgeries included 5-FU, cisplatin, FOLFOX, capecitabine and S-1. Docetaxel was not the routine first line chemotherapy regimen. From NCCN introduction, DCF was recommended as first line chemotherapy for metastatic or locally advanced cancer [@pone.0060320-Ajani5]. It might raise the question whether or not DCF regimen could be used in postoperative adjuvant chemotherapy and have better survival outcomes than traditional adjuvant chemotherapy.

In our review, 9 out of 12 RCTs came from China, in which the population was small and follow-up time was short. Their aim was to evaluate the short term outcomes, ORR and toxicities. Only three RCTs including a foreign one reported the survival rate. This might influence the analysis in our review. More RCTs with longer follow-up time are needed.

Conclusion {#s4a}
----------

DCF regimen had better response than non-taxane containing regimen and could potentially improve the survival outcomes. The chemotherapy-related toxicity of DCF regimen is also acceptable to some extent. At the same time, more high-quality RCTs are needed to decide on the effectiveness of DCF regimen.
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